MASP-2 Inhibitors and Methods of Use
ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Summary
The European Patent Office published patent application EP4069678A1 for Omeros Corporation, covering MASP-2 (Mannose-Associated Serine Protease-2) inhibitors and their therapeutic methods of use. The patent specifies compound compositions, methods of synthesis, and applications across multiple therapeutic areas including immunological, metabolic, and inflammatory disorders.
What changed
The EPO published Omeros Corporation's European patent application EP4069678A1 for MASP-2 inhibitors. The patent includes claims covering compound compositions of matter (classified under C07D 211/60, C07D 403/14, C07D 413/12), pharmaceutical formulations (A61K compounds), and methods of treatment for conditions including metabolic disorders (A61P 3/00), coagulation disorders (A61P 7/00, A61P 7/02), cardiovascular disease (A61P 9/00), respiratory conditions (A61P 11/00), renal disease (A61P 13/00), ocular conditions (A61P 27/02), inflammation (A61P 29/00), and immune disorders (A61P 37/00).
Pharmaceutical companies developing complement system inhibitors or therapeutic programs targeting MASP-2 pathways should review the patent claims to assess freedom-to-operate implications. Generic manufacturers and biosimilar developers should evaluate potential blocking positions. No immediate compliance actions are required as this is a patent publication rather than an enforcement action.
What to do next
- Review patent EP4069678A1 claims to assess freedom-to-operate for MASP-2 inhibitor programs
- Evaluate potential licensing or design-around opportunities if developing complement pathway therapeutics
- Monitor for subsequent grant of patent and associated validation states
Source document (simplified)
MASP-2 INHIBITORS AND METHODS OF USE
Publication EP4069678A1 Kind: A1 Mar 25, 2026
Applicants
Omeros Corporation
Inventors
CUTSHALL, Neil S., GAGE, Jennifer Lynn, GOLDSTEIN, Sara Rebecca, KESHIPEDDY, Santosh Kumar, KWON, Do Yeon, LEMUS, Robert Huerta, LITTLE, Thomas L., METZ, Markus, NOLLERT VON SPECHT, Peter Kurt, PRICE, Loren Michael, TSOUNG, Jennifer
IPC Classifications
C07D 211/60 20060101AFI20210611BHEP C07D 403/14 20060101ALI20210611BHEP C07D 413/12 20060101ALI20210611BHEP C07F 9/38 20060101ALI20210611BHEP A61P 3/00 20060101ALI20210611BHEP A61P 7/00 20060101ALI20210611BHEP A61P 7/02 20060101ALI20210611BHEP A61P 9/00 20060101ALI20210611BHEP A61P 11/00 20060101ALI20210611BHEP A61P 13/00 20060101ALI20210611BHEP A61P 27/02 20060101ALI20210611BHEP A61P 29/00 20060101ALI20210611BHEP A61P 37/00 20060101ALI20210611BHEP A61K 31/662 20060101ALI20210611BHEP A61K 31/4418 20060101ALI20210611BHEP A61K 31/4439 20060101ALI20210611BHEP A61K 31/4436 20060101ALI20210611BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.